Continuous Action Recognition Based on Sequence Alignment

Continuous action recognition is more challenging than isolated recognition because classification and segmentation must be simultaneously carried out. We build on the well known dynamic time warping (DTW) framework and devise a novel visual alignment technique, namely dynamic frame warping (DFW), which performs isolated recognition based on per-frame representation of videos, and on aligning a test sequence with a model sequence. Moreover, we propose two extensions which enable to perform recognition concomitant with segmentation, namely one-pass DFW and two-pass DFW. These two methods have their roots in the domain of continuous recognition of speech and, to the best of our knowledge, their extension to continuous visual action recognition has been overlooked. We test and illustrate the proposed techniques with a recently released dataset (RAVEL) and with two public-domain datasets widely used in action recognition (Hollywood-1 and Hollywood-2). We also compare the performances of the proposed isolated and continuous recognition algorithms with several recently published methods

Diffuse Coplanar Surface Barrier Discharge in Nitrogen: Microdischarges Statistical Behavior

We studied statistical behavior of microdischarges of diffuse coplanar surface barrier discharge (DCSBD) operated in nitrogen atmosphere at two input voltage regimes. We measured spectrally unresolved discharge patterns together with discharge electrical parameters using highspeed iCCD camera and digital storage oscilloscope. External synchronization enabled us to measure the discharge pattern during positive and/or negative half-period of input high voltage in the single-shotmode of operation. The comparison of microdischarges behavior during positive, negative and both half periods of input high voltage was performed for two levels of input voltage, i.e. voltage slightly above ignition voltage and high above ignition voltage (“overvoltage”). The number of microchannels crossing discharge gap was counted and compared with number of microdischarge current peaks observed during corresponding half-period of input high voltage. The relations of those incidences was shown and discussed

Nanoindentation induced reversible plasticity detected by acoustic emission

Please click Additional Files below to see the full abstract

Scene Flow Estimation by Growing Correspondence Seeds

International audienceA simple seed growing algorithm for estimating scene flow in a stereo setup is presented. Two calibrated and synchronized cameras observe a scene and output a sequence of image pairs. The algorithm simultaneously computes a disparity map between the image pairs and optical flow maps between consecutive images. This, together with calibration data, is an equivalent representation of the 3D scene flow, i.e. a 3D velocity vector is associated with each reconstructed point. The proposed method starts from correspondence seeds and propagates these correspondences to their neighborhood. It is accurate for complex scenes with large motions and produces temporallycoherent stereo disparity and optical flow results. The algorithm is fast due to inherent search space reduction. An explicit comparison with recent methods of spatiotemporal stereo and variational optical and scene flow is provided

Research on using the Tecnomatix Plant Simulation for simulation and visualization of traffic processes at the traffic node

Simulation software Tecnomatix Plant Simulation was originally created for a modelling and subsequent simulation of production and logistics processes. Its variability, however, opens its use also in other areas such as transport in urban agglomerations. Based on that, research was implemented to verify the program's application in urban transport, specifically to visualize and simulate traffic processes at the traffic node. The paper describes a methodology which made it possible to create a simulation program for traffic light intersections, and presents examples of the simulation model application. The proposed methodology will enable the application of Tecnomatix Plant Simulation to create a complex simulation model of the logistics process. It will mainly enable to simulate the field of production logistics and city logistics within one simulation model.Kultúrna a Edukacná Grantová Agentúra MŠVVaŠ SR, KEGA: 005TUKE-4/2022, 018TUKE-4/2022, 313011T567, APVV-21-0195, IGA/FLKŘ/2022/001, RVO/FLKŘ/2022/0

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts. June 4-7, 2019, Szczyrk, Polan

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation